\_\_\_\_\_\_

Sequence Listing was accepted.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)

217-9197 (toll free).

Reviewer: markspencer

Timestamp: [year=2009; month=10; day=30; hr=11; min=6; sec=8; ms=400; ]

\_\_\_\_\_

## Validated By CRFValidator v 1.0.3

Application No: 10540228 Version No: 1.0

Input Set:

Output Set:

**Started:** 2009-10-15 18:26:15.686

Finished: 2009-10-15 18:26:16.899

**Elapsed:** 0 hr(s) 0 min(s) 1 sec(s) 213 ms

Total Warnings: 5

Total Errors: 4

No. of SeqIDs Defined: 6

Actual SeqID Count: 6

Error code		Error Description
W	213	Artificial or Unknown found in <213> in SEQ ID (2)
E	257	Invalid sequence data feature in <221> in SEQ ID (2)
W	213	Artificial or Unknown found in <213> in SEQ ID (3)
W	213	Artificial or Unknown found in <213> in SEQ ID (4)
W	213	Artificial or Unknown found in <213> in SEQ ID (5)
E	257	Invalid sequence data feature in <221> in SEQ ID (5)
E	257	Invalid sequence data feature in <221> in SEQ ID (5)
W	213	Artificial or Unknown found in <213> in SEQ ID (6)
E	257	Invalid sequence data feature in <221> in SEQ ID (6)

## SEQUENCE LISTING

```
<110> LOUMAYE, ERNEST
<120> USE OF GNRH AGONISTS TO SUPPORT THE LUTEAL PHASE DURING
     INFERTILITY TREATMENT
<130> KZY-001US
<140> 10540228
<141> 2009-10-15
<150> PCT/IB2003/006205
<151> 2003-12-29
<150> 60/448,468
<151> 2003-02-21
<150> FR 0216810
<151> 2002-12-27
<160> 6
<170> PatentIn version 3.5
<210> 1
<211> 10
<212> PRT
<213> Homo sapiens
<400> 1
Glu His Trp Ser Tyr His Leu Arg Pro Gly
              5
                                  10
<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic peptide
<220>
<221> MOD_RES
<222> (6)..(6)
<223> t-butylserine
<400> 2
Glu His Trp Ser Tyr Ser Leu Arg Pro
        5
<210> 3
```

<211> 9

```
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic peptide
<400> 3
Glu His Trp Ser Tyr Leu Leu Arg Pro
<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic peptide
<400> 4
Glu His Trp Ser Tyr Trp Leu Arg Pro Gly
               5
<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic peptide
<220>
<221> MOD_RES
<222> (6)..(6)
<223> t-butylserine
<220>
<221> MOD_RES
<222> (10)..(10)
<223> aza-glycine
<400> 5
Glu His Trp Ser Tyr Xaa Leu Arg Pro Xaa
              5
<210> 6
<211> 10
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic peptide
```

```
<220>
<221> MOD_RES
<222> (6)..(6)
<223> 2-Naphthylalanine

<400> 6
Glu His Trp Ser Tyr Xaa Leu Arg Pro Gly
1 5 10
```